Get the Stockscreener App
7.33
3.68%
0.26
Pre-market:
7.56
0.23
+3.14%
Cogent Biosciences Inc stock is traded at $7.33, with a volume of 2.22M.
It is up +3.68% in the last 24 hours and up +52.07% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$7.07
Open:
$7.1
24h Volume:
2.22M
Relative Volume:
1.48
Market Cap:
$844.81M
Revenue:
-
Net Income/Loss:
$-242.30M
P/E Ratio:
-2.9556
EPS:
-2.48
Net Cash Flow:
$-192.10M
1W Performance:
+1.24%
1M Performance:
+52.07%
6M Performance:
-6.86%
1Y Performance:
-9.51%
1-Day Range:
$7.03
$7.50
1-Week Range:
$6.92
$7.50
52-Week Range:
$3.72
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
7.33 | 844.81M | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
(COGT) Investment Analysis - news.stocktradersdaily.com
Cogent Biosciences (NASDAQ:COGT) Given “Hold” Rating at Needham & Company LLC - Defense World
Cogent Biosciences (COGT) Receives Reiterated 'Hold' Rating by N - GuruFocus
Cogent Biosciences (COGT) Receives Reiterated 'Hold' Rating by Needham | COGT Stock News - GuruFocus
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.57 - Defense World
Bank of America Corp DE Reduces Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Term Loan Facility - Leerink Partners
Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Position Lowered by California State Teachers Retirement System - Defense World
Latham & Watkins Leads on US$400 Million Debt Financing Facility for Cogent Biosciences - Latham & Watkins LLP
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - GlobeNewswire
Cogent Biosciences Secures $400 Million in Financing - citybiz
Cogent Biosciences, Inc. announced that it expects to receive $400 million in funding - MarketScreener
Cogent Biosciences Gets $400 Million Debt Financing - MarketScreener
Cogent Biosciences (COGT) Secures $400M Financing for Growth Ini - GuruFocus
Cogent Secures Up To $400 Mln Debt Facility From SLR Capital For Growth Strategy - Nasdaq
Cogent Biosciences Secures $400 Million Debt Financing Facility to Support Growth and Upcoming Bezuclastinib Launch - Nasdaq
Cogent Biosciences Lands Massive $400M Financing Deal as 3 Pivotal Trial Results Loom in 2025 - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 17,741 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Two Sigma Investments LP Sells 4,633 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Two Sigma Advisers LP Has $148,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Ameriprise Financial Inc. Acquires 9,459 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
(COGT) On The My Stocks Page - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $2.44 Million Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
ProShare Advisors LLC Increases Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.7% – Time to Sell? - Defense World
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $25.00 at JPMorgan Chase & Co. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Shares Up 11.6% Following Analyst Upgrade - Defense World
COGT: JP Morgan Raises Price Target for Cogent Biosciences | COG - GuruFocus
Cogent Biosciences Announces Participation in the Jefferies Glob - GuruFocus
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewswire
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference | COGT Stock News - GuruFocus
JPMorgan Ups Price Target for Cogent Biosciences (COGT) to $25 | - GuruFocus
Cogent Biosciences Reveals Latest Precision Therapy Progress Plus New Employee Stock Options - Stock Titan
Deutsche Bank AG Reduces Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Jane Street Group LLC Decreases Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - simplywall.st
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
BNP Paribas Financial Markets Buys Shares of 66,784 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Janus Henderson Group PLC Has $227,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Q2 EPS Estimate for Cogent Biosciences Raised by Analyst - Defense World
HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price - Defense World
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) PT at $14.29 - Defense World
Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted P - GuruFocus
Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted Price Target | COGT Stock News - GuruFocus
Cogent Biosciences (COGT) Price Target Reduced by H.C. Wainwrigh - GuruFocus
Northern Trust Corp Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Where are the Opportunities in (COGT) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Has $388,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade - MSN
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):